Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease

References

• Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111: 2962–2972.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, . A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD. Blood 2009;114(Suppl. 1): Abstract 351.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Cibeira MT, Martinez J, . Thalidomide/dexamethasone (TD) vs. bortezomib (Velcade)®/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcade® as induction regimens prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA/GEM trial. Blood 2009;114(Suppl. 1): Abstract 130.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, van der Holt B, Schmidt-Wolf IGH, . First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Blood 2008;112(Suppl. 1): Abstract 653.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, . Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075–2085.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, . Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679–686.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, . Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892–3901.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Kendall T, Al-Zoubi A, . Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009;27:5015–5022.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martinez-Lopez J, . Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934–941.
   PubMed Web of Science ®Google Scholar
• Hassoun H, Reich L, Klimek VM, . Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006;132:155–161.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, . Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414–423.
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, . A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, . International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Laroche M, Attal M, Dromer C. Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clin Rheumatol 1996;15:347–352.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010;28:2612–2624.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139–3146.
   PubMed Web of Science ®Google Scholar
• Yoon S-S, Kim HJ, Chung JS, . Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (bortezomib, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with bortezomib for newly diagnosed multiple myeloma: final analysis of phase II trial. Blood 2008;112(Suppl. 1): Abstract 3330.
   Google Scholar
• Evans WK, Feld R, Murray N, . Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987;107:451–458.
   PubMed Web of Science ®Google Scholar
• Thomas E, Holmes FA, Smith TL, . The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004;22:2294–2302.
   PubMed Web of Science ®Google Scholar
• Bernard JL, Philip T, Zucker JM, . Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen? J Clin Oncol 1987;5:1952–1959.
   PubMed Web of Science ®Google Scholar
• >Vesole DH, Jacobus S, Rajkumar SV, ; Eastern Cooperative Oncology Group. Lenalidomide plus low-dose dexamethasone (Ld): superior one and two year survival regardless of age compared to lenalidomide plus high-dose dexamethasone (LD). Blood 2010;116(Suppl. 1): Abstract 308.
   Google Scholar
• Laura R, Cibeira MT, Uriburu C, . Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006;76:405–408.
   PubMed Web of Science ®Google Scholar
• Davies RG, De P, Child DF, . Euglycaemic diabetic ketoacidosis. Hosp Med 2003;64:557–558.
   PubMed Web of Science ®Google Scholar
• Piva SR, Erhard RE, Childs JD, . Reliability of measuring iliac crest level in the standing and sitting position using a new measurement device. J Manipulative Physiol Ther 2003;26:437–441.
   PubMed Web of Science ®Google Scholar
• Childers NK, Greenleaf C, Li F, . Effect of age on immunoglobulin A subclass distribution in human parotid saliva. Oral Microbiol Immunol 2003;18:298–301.
   PubMedGoogle Scholar
• Mateos M-V, Richardson PG, Schlag R, . Bortezomib plus melphalan-prednisone continues to demonstrate a survival benefit vs melphalan-prednisone in the phase III VISTA trial in previously untreated multiple myeloma after 3 years’ follow-up and extensive subsequent therapy use. Blood 2009;114(Suppl. 1): Abstract 3859.
   PubMed Web of Science ®Google Scholar
• Hoering A, Crowley J, Shaughnessy JD Jr, . Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood 2009;114:1299–1305.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Lonial S, Jakubowiak AJ, . High response rates and encouraging time-to-event data with lenalidomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma: final results of a phase I/II study. Blood 2009;114(Suppl. 1): Abstract 1218.
   Google Scholar
• Reeder CB, Reece DE, Kukreti V, . Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337–1341.
   PubMed Web of Science ®Google Scholar